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ABSTRACT
Introduction: Fewer than half of all people at highest
risk of a cardiovascular event are receiving and adhering
to best practice recommendations to lower their risk. In
this project, we examine the role of an e-health-assisted
consumer-focused strategy as a means of overcoming
these gaps between evidence and practice. Consumer
Navigation of Electronic Cardiovascular Tools
(CONNECT) aims to test whether a consumer-focused
e-health strategy provided to Aboriginal and Torres
Strait Islander and non-indigenous adults, recruited
through primary care, at moderate-to-high risk of a
cardiovascular disease event will improve risk factor
control when compared with usual care.
Methods and analysis: Randomised controlled trial
of 2000 participants with an average of 18 months of
follow-up to evaluate the effectiveness of an integrated
consumer-directed e-health portal on cardiovascular
risk compared with usual care in patients with
cardiovascular disease or who are at moderate-to-high
cardiovascular disease risk. The trial will be augmented
by formal economic and process evaluations to assess
acceptability, equity and cost-effectiveness of the
intervention. The intervention group will participate in a
consumer-directed e-health strategy for cardiovascular
risk management. The programme is electronically
integrated with the primary care provider’s software and
will include interactive smart phone and Internet
platforms. The primary outcome is a composite
endpoint of the proportion of people meeting the
Australian guideline-recommended blood pressure (BP)
and cholesterol targets. Secondary outcomes include
change in mean BP and fasting cholesterol levels,
proportion meeting BP and cholesterol targets
separately, self-efficacy, health literacy, self-reported
point prevalence abstinence in smoking, body mass
index and waist circumference, self-reported physical
activity and self-reported medication adherence.
Ethics and dissemination: Primary ethics approval
was received from the University of Sydney Human
Research Ethics Committee and the Aboriginal Health
and Medical Research Council. Results will be
disseminated via the usual scientific forums including
peer-reviewed publications and presentations at
international conferences
Clinical Trials registration number:
ACTRN12613000715774.
INTRODUCTION
Cardiovascular disease burden
Cardiovascular disease (CVD), including cor-
onary heart disease and stroke, is the leading
Strengths and limitations of this study
▪ In this project, we will examine the role of an inte-
grated e-health consumer strategy as a means of
overcoming such health system inefficiencies.
▪ The Consumer Navigation of Electronic
Cardiovascular Tools (CONNECT) study will gen-
erate rigorously evaluated findings on an issue of
national and international importance.
▪ The development of a content-rich, consumer-
focused e-health intervention that is fully inte-
grated with primary healthcare system will
greatly inform the e-health agenda.
▪ If effective, the CONNECT e-health strategy could
be upscaled and expanded to increase compli-
ance with international e-health strategies. The
CONNECT strategy may also have applicability as
a standalone strategy where electronic integration
with primary care is unavailable.
▪ Potential limitations are that this is an Australian
study and relies on integration with the Australian
personally controlled e-health record. In addition,
the intervention is primarily consumer driven.
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cause of death and disease burden globally.1
Importantly, in Australia, Aboriginal and Torres Strait
Islander peoples experience approximately ﬁve times
greater CVD burden than other Australians.2 Fewer than
50% of adults who attend Australian general practice or
Aboriginal Community Controlled Health Services
(ACCHSs) are adequately screened for vascular risk, and
for those identiﬁed at high risk, only about 40% are
receiving best practice care.3–5 Similar ﬁndings have
been noted in other Australian studies.6–9 Adherence
rates to lifestyle modiﬁcation are around 30%10 and
adherence to recommended medicines may be as low as
50% after 6 months of therapy.11 Overall, these studies
have demonstrated failure to adequately implement
effective interventions (that are also adhered to) to
lower CVD risk for those who need it most.
Consumer-focused e-health interventions
During the past decade, there has been rapid develop-
ment in consumer e-health. Several studies have shown
the beneﬁts of interactive Internet portals for managing
chronic conditions (asthma,12–14 type 2 diabetes,15
arthritis,16 hypertension17 and mental health18 19), for
health behaviour change20 21 and lifestyle risk factors
(physical activity,22 smoking cessation23 and weight
loss).24 A Cochrane review of 124 studies concluded that
computer-based ‘Interactive Health Communication
Applications’ can also improve cognitive and social out-
comes of patients with chronic conditions.25 The emer-
ging evidence on text message interventions also
appears promising. Five randomised controlled trials
(RCTs) have demonstrated the effectiveness of mobile
phone text messaging to promote smoking cessation,26 27
and a number of small RCTs have shown improved out-
comes related to weight loss,28 physical activity,29 asthma
medication adherence,30 glycaemic control in diabetes,31
blood pressure (BP) lowering,32 liver transplantation33
and HIV treatment.34 Other studies looking at text mes-
saging systems to improve adherence to lifestyle and
medication recommendations for people with estab-
lished coronary artery disease are ongoing.35 36
Although the evidence for consumer-focused interven-
tions is promising, there are few randomised evaluations
of personally controlled e-health records (PCEHRs).37
The PCEHR is the Australian secure online summary of
an individual’s health information. This e-health record
allows people, their doctors, hospitals and other health-
care providers to view and share health information and
ideally improve care. Most studies investigating online
personal health records have had small sample sizes and
short follow-up periods (<12 months). This raises con-
cerns about their external validity and sustainability.
One Australian system which features a personal health
record, tools to assist with making decisions, organising
tasks and a social networking feature has been shown in
a community-based trial to promote improved uptake of
inﬂuenza vaccination among university students.38 We
are not aware of any RCTs that have incorporated
multiple e-health components as part of a multifaceted,
complex intervention for chronic disease management
and prevention. Critically, there are no trials involving
Aboriginal and Torres Strait Islander peoples, and
attempts to integrate consumer strategies with Australian
primary healthcare electronic health records are at a
very early stage.
Digital technologies and access
Equitable digital access is critical to implementation of
the national e-health strategy. Digital access is growing
exponentially in Australia. In 2010–2011, 79% of
Australian households had access to the Internet in their
home and 77% of these used the Internet daily.39
Among Aboriginal and Torres Strait Islander adults, in
2008, 59% had Internet access (up from 41% in
2002).40 Mobile phone use has been dramatically rising
and now outstrips computer access. In 2006–2007, 81%
of Australian consumers reported owning a mobile
phone. Although growth was originally driven by the
younger market, the largest annual increase in mobile
phone ownership is among people aged 65+ years.41
Data on mobile phone access for Aboriginal and Torres
Strait Islander people are unclear; however, in 2008,
67% of non-remote and 61% of remote households had
access to a prepaid mobile phone, and 41% and 19% of
non-remote and remote households, respectively, had
mobile access via a contract.41 ‘Smart phones’, charac-
terised by multimedia and Internet connectivity, are the
biggest growth area. In 2010–2011, around 25% (3.9
million people) of Australians accessing the Internet did
so via their phone (up 63% on the previous year).42
HealthTracker e-health system
An electronic patient care system called HealthTracker
has been previously developed and tested by our
research team.43 This e-health system is essentially a clin-
ical decision support system for CVD risk management
in primary care. HealthTracker is fully integrated with
the primary healthcare electronic health record and
provides: (1) point of care decision support related to
CVD prevention and management; (2) a graphical
patient counselling tool; (3) a computerised audit tool
that provides rapid snapshots on health service perform-
ance combined with a recall and reminder system and
(4) access to a quality improvement web-based portal
where health services can view monthly peer-ranked per-
formance and access tools and resources to support
quality care. HealthTracker has undergone signiﬁcant
proof of concept testing and validation,43–45 and is cur-
rently being implemented in a large-scale cluster RCT
(TORPEDO) in Australia.42 The trial is funded by the
Australian National Health and Medical Research
Council and involves 20 ACCHSs, 40 general practices
and over 50 000 patients (Grant ID #1010547,
ACTRN12611000478910). However, HealthTracker is a
provider-directed strategy and the added value of a con-
sumer or patient-focused interface remains unknown.
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Therefore, the Consumer Navigation of Electronic
Cardiovascular Tools (CONNECT) study aims to
enhance the existing HealthTracker system and utilise
the growing e-health environment to scientiﬁcally test
whether a consumer-focused e-health strategy provided
to Aboriginal and Torres Strait Islander as well as non-
indigenous people at moderate-to-high risk of a CVD
event will improve risk factor control when compared
with usual healthcare. The study also aims to determine
the acceptability, equity and cost-effectiveness of such a
strategy. We hypothesise that access to an integrated and
patient-centred e-health strategy will improve risk factor
control when compared with usual healthcare.
Methods and analysis
Study design
CONNECT is a single blind, RCT involving 2000 regular
adult health service attendees at General Practices
and ACCHSs with an average follow-up of 18 months
(ﬁgure 1). Written and informed consent will be obtained
from all participants.
The study will be conducted across approximately 65
Australian General Practices and ACCHSs. Participants
with a diagnosis of CVD or who are at high risk of CVD
will be randomly allocated to either the control or inter-
vention group. The control group will continue to par-
ticipate in usual healthcare, supported by
HealthTracker; the intervention group will participate in
the CONNECT programme which is a consumer-
directed e-health strategy for cardiovascular risk manage-
ment. The programme is electronically integrated with
the primary care provider’s software and will include
access to interactive smart phone and Internet
platforms. Control arm participants will not have access
to the portal. However, at the end of study, all partici-
pants (control and intervention) will be offered portal
access for a maximum of 12 months. Participants will be
assessed by personnel blinded to treatment allocation at
face-to-face appointments at baseline and 12 months
and at the end of study.
Randomisation
Eligible consenting participants will be randomly
assigned to the e-health strategy or provision of usual
care for an average of 18 months (minimum 12 months
and maximum 24 months). In both groups, any advice
and/or other interventions provided by the general
practitioner (GP)/health service will continue at their
health provider’s discretion. Randomisation will be con-
ducted independently using a central computer-based
randomisation service with equal allocation to interven-
tion versus control. A permuted block sequence will be
used and will be stratiﬁed by level of CVD risk, study
centre and Aboriginal and/or Torres Strait Islander
status. Study personnel taking follow-up assessments will
also be blinded to parallel group assignments.
Participant eligibility
Consenting adult patients (>18 years) with access to the
Internet at least once a month via mobile phone, tablet
or computer who are at moderate-to-high risk of a CVD
event will be included. Potential participants will be
excluded if they have a severe intellectual disability or if
they have insufﬁcient English knowledge to provide
written informed consent. Moderate-to-high CVD risk is
deﬁned as any of the following:
1. Five-year CVD risk ≥10% using the Framingham risk
equation;
2. A clinically high risk condition (Aboriginal/Torres
Strait Islander and age >75 years, diabetes and age
>60 years, diabetes and albuminuria, epidermal
growth factor receptor <45 mL/min, systolic BP
≥180 mm Hg, diastolic BP ≥110 mm Hg and total
cholesterol >7.5 mmol)46;
3. An established CVD diagnosis (ischaemic heart
disease, stroke/transient ischaemic attack and periph-
eral vascular disease).
Recruitment
We will aim to recruit approximately 30 participants
from each of a total of 65 general practices and
ACCHSs. Eligible patients will be identiﬁed by clinic staff
using a customised electronic data extraction facility in
the practice software system47 which was successfully
used in the TORPEDO trial.43 Potential participants will
receive an invitation letter from their GP. Eligibility will
then be conﬁrmed during a telephone call from a study
research assistant. The interested individuals will be
invited to a face-to-face registration visit at the practice
from which they were identiﬁed. At the initial visit,
written informed consent will be obtained and the
Figure 1 The Consumer Navigation of Electronic
Cardiovascular Tools (CONNECT) study schema.
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baseline assessment will be completed by a CONNECT
research assistant. Practices will be reimbursed a small
fee (in line with a standard consultation fee) for the
time required to assist with recruitment if the minimum
of 25 patients per practice are recruited. All software
license costs and technical support associated with the
HealthTracker system will be provided free for the dur-
ation of the trial.
Intervention
The intervention group will participate in the
CONNECT programme, which is a consumer-focused
e-health strategy aimed at assisting with the management
and prevention of CVD (ﬁgure 2). The programme
components focus on cardiovascular risk assessment,
medication adherence, lifestyle change and seamless
patient-provider communication. CONNECT content
has been informed by a detailed analysis of factors that
drive uptake of Internet-based programmes for CVD sec-
ondary prevention.48 HealthTracker assessment data
(eg, CVD risk factors and scores, medications and other
treatment advice) are uploaded securely to a consumer-
focused CVD-speciﬁc module built using a e-health
record architecture. Patients will then be able to securely
register for access to the integrated portal. Throughout
the trial, a minimum of one upload from their software
to the CONNECT portal will be performed by the GP or
an authorised staff member for participants randomised
to the intervention. Subsequent uploads to the
CONNECT system will be at the discretion of the
treating practitioner and will depend on visit frequency
and availability of new data (based on changes in patient
care and frequency of visits). An alert will be ﬂagged in
the application if a new upload has occurred.
CONNECT was systematically developed through an
iterative process and using user-centred design
approach.49 The intervention development process
involved collaborative design workshops (including
journey mapping and persona building),49 sketching
and iterative validation by consumers.
The portal will be accessible via the Internet and also
via a downloadable application for use on a mobile
device. As described in ﬁgure 2, participants in the inter-
vention arm will be able to securely access the consumer
portal via a secure login process. Patient data will be
electronically uploaded from the clinic record to the
portal. As part of the intervention, an implementation
team of ‘CONNECT coordinators’ will provide
face-to-face training to participants on how to use the
various features in the portal. Key training features
include: (1) viewing personal health record summary
including information such as medicines, test results, BP
and weight; (2) use of interactive tools and resources
(eg, the HealthTracker risk calculator that visually plots
CVD risk projections and allows people to perform
‘what if scenarios’ to explore the relative risk reductions
(RRRs) from various CVD risk factors); (3) access to
simple medication and healthy lifestyle reminders and
motivational message prompts depending on their
choice and health proﬁle (eg, smokers wanting to quit
Figure 2 The consumer-focused e-health strategy linked to primary healthcare.
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will be able to receive a series of random messages to
assist with cessation) and (4) an interactive goal setting
and social media feature where people will be able to set
their own goals and receive virtual rewards and also com-
municate with other users using CONNECT. As part of
the intervention, participants will be contacted at
months one and two by telephone and additional
support will be provided as needed. At any time, assist-
ance will also be available via a helpdesk number or via
an online or mobile text help request. A CONNECT
coordinator will receive these requests and provide
appropriate medical support or arrange technical advice
if needed. The CONNECT coordinators will be separate
from the recruitment and assessment team so as to
maintain blinding of outcome assessments.
Control group
Participants in the intervention and control groups will
continue with usual healthcare. Control arm participants
will not have access to the portal; however, at the end of
study, all participants (control and intervention) will be
offered portal access for a maximum of 12 months.
Data collection and study outcomes
Centrally employed CONNECT research assistants
(blinded to group allocation) will conduct study visits at
baseline, 12 and 24 months and ensure all clinical mea-
sures are entered into a purpose-built and secure online
database. Clinical and survey data will be collected via
face-to-face or phone interviews (if necessary) and
entered into a secure central web-based database.
During 12-month and 24-month assessments, we will
assess the access to CVD management services for both
groups such as the frequency of GP and specialist visits
(self-report), access to allied health services (eg, dietitian
and psychologists) and community groups or activities
(eg, local walking group, online smoking cessation pro-
gramme). In addition, analytic information from the
CONNECT portal and smartphone application will be
extracted on a monthly basis to determine usage pat-
terns (website and smartphone/tablet application). This
study will be monitored and managed centrally with
periodic site monitoring visits.
The primary endpoint is the proportion of partici-
pants at the end of study whose BP and fasting low-
density lipoprotein (LDL) cholesterol are meeting the
Australian guideline targets (deﬁned as: ≤130/80 for
participants with CVD, diabetes or albuminuria OR
≤140/90 mm Hg for all others participants) and
LDL-cholesterol < 2 mmol/L).50 Secondary outcomes
include the mean difference from baseline in systolic
and diastolic BP and fasting LDL cholesterol levels, pro-
portion meeting BP and LDL targets separately, self-
efﬁcacy, health literacy, self-reported point prevalence
abstinence in smoking, mean difference from baseline
in body mass index and waist circumference, self-
reported physical activity and self-reported medication
adherence (box 1).
Statistical considerations
For the primary outcome measure, assumptions used in
the sample size and power estimates have been deter-
mined from TORPEDO data of 10 181 routinely attend-
ing patients at moderate-to-high CVD risk. Calculations
assume that 25% of people are meeting guideline-
recommended BP and LDL targets (as deﬁned above)
at baseline with mean systolic BP 136 mm Hg (SD 17.2)
and mean LDL cholesterol 2.5 mmol (SD 0.70). A total
sample size of 2000 participants, allowing for a 20% loss
Box 1 Primary and secondary outcomes (measured at
baseline, 12 months and end of study)
Primary
Proportion of participants meeting the Australian guideline BP
and lipid targets50
▸ BP of 140/90 mmHg for all except those with CVD, diabetes
or albuminuria for whom the target BP is 130/80 mmHg. BP
measurement is conducted via three resting and sitting digital
recordings with the mean of the last two readings.
▸ LDL of <2.0mmol/L. LDL measurement is via fasting blood
sample.
BP is based, on an average, of three resting and sitting digital
recordings with the mean of last two readings, and LDL-cholesterol
is measured on a fasting blood sample.
Secondary
▸ Proportion meeting guideline-recommended BP and
LDL-cholesterol targets separately
▸ Difference in mean systolic and diastolic BP at the end of
study
▸ Difference in mean cholesterol levels at the end of study (TC,
LDL and HDL)
▸ Difference in mean body mass index and waist circumference
at the end of study
▸ Difference in health literacy scores—HLQ51 and the eHEALS52
at the end of study
▸ Cardiovascular and renal events, new onset diabetes—self
report and confirmed with medical records
▸ Physical activity—WHO Global Physical Activity
Questionnaire53
▸ Point abstinence in smoking (≤5 cigarettes in the previous
7 days54 or recent smoking according to assessment using
carbon monoxide meter)
▸ Fruit and vegetable intake, fish, salt and saturated fat intake—
self-report portions consumed in 7 days prior and compared
with published guidelines recommendations
▸ Cardioprotective medication adherence—self-report and veri-
fied by medical record and pharmaceutical benefits scheme
data
▸ All-cause mortality—medical record
▸ Hospital readmissions—self-report and verified by medical
record
▸ Health-related quality of life—EQ5D (version 5L with
Australian standardised weights55)
BP, blood pressure; CVD, cardiovascular disease; eHEALS,
e-health Literacy Scale; HDL, high-density lipoprotein; HLQ,
Health Literacy Questionnaire; LDL, low-density lipoprotein; TC,
total cholesterol.
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to follow-up, would have 90% power to detect an abso-
lute improvement of at least 7.5% in the proportion of
people meeting recommended targets using two-sided
tests, with p values of less than 0.05 judged as signiﬁcant.
For secondary outcomes, this translates to a 2.8 mm Hg
absolute difference in systolic BP and a 0.11 mmol/L
absolute difference in LDL cholesterol.
Although there is little literature on effect sizes of
e-health interventions for CVD risk factors, we have
powered the study on effect estimates that could be con-
sidered clinically meaningful for a moderate-to-high risk
population. Based on previous work on modelling car-
diovascular risk factor reductions, the BP and LDL chol-
esterol effect sizes mentioned above could each translate
to around 5–10% RRR or combined RRR of 10–19% in
cardiovascular events.56
Primary analyses will be unadjusted, following an
intention-to-treat principle, and conducted blind to
treatment allocation. If necessary, multivariate analyses
will be performed to adjust for any signiﬁcant differ-
ences between each study arm. Prespeciﬁed analyses will
be conducted on the following subgroups: established
CVD versus high-risk non-CVD; Aboriginal versus
non-Aboriginal; proportion meeting/not meeting the
primary endpoint at baseline; proportion adherent/not
adherent to guideline-recommended BP and lipid medi-
cines at baseline. Characteristics will be compared
between groups using independent t tests for continuous
variables and χ² tests for categorical variables. Mean risk
factor levels will be compared between groups in terms
of relative risks, 95% CIs and two-sided p values.
Mann-Whitney U tests will be used where data are not
normally distributed.
Process evaluation
Process evaluations explore the implementation, receipt
and setting of an intervention and help in the interpret-
ation of outcome results.57 Our team has extensive
experience in such evaluations.44 48 58 Analyses will be
conducted by the Pawson and Tilley59 realistic evaluation
model, which seeks to understand human actors’
choices and actions, within the context of the systems in
which these players operate. We will use mixed methods
to investigate why the e-health strategy may or may not
have been effective and which intervention components
were most inﬂuential. Four data sources will be used: (1)
quantitative data on patient measures described above;
(2) usage of data extracted directly from the consumer
portal; (3) patient and provider surveys of satisfaction,
tool utility and health actions taken and (4) semistruc-
tured interviews with participants and care providers
(including GPs) toward the end of study.
Multivariate subgroup analyses will assess for any dif-
ferential impact of the intervention on outcome mea-
sures by Aboriginal status, postcode, income, education
level, language spoken at home, age, gender and inter-
net and mobile phone access. Qualitative data will
explore participant views on beneﬁts, disadvantages and
acceptability of the portal. Taking an equity perspective,
interviews will seek to understand barriers and enablers
to uptake by particular subpopulations, including factors
such as Internet/smartphone connectivity and geo-
graphical remoteness. To obtain a broad range of views,
we will use a maximum variation sampling method
based on patient demographics and health service
characteristics.60 Sampling will continue until no new
themes or categories emerge (‘thematic saturation’). We
anticipate, based on our previous experience, around 80
interviews will be required. In ACCHSs, Aboriginal parti-
cipants will be interviewed by Aboriginal researchers. As
with previous research collaborations, support and train-
ing will be provided for Aboriginal health researchers in
the process evaluation, focusing not only on data collec-
tion but also on analysis and reporting. Analyses will be
thematic and coding will be carried out inductively
based on emergent themes. NVivo V.9 will be used to
assist with interview data management. Given the focus
of CONNECT on consumer engagement with an
e-health strategy, assessment of health literacy (including
communication with providers and understanding of
information provided) will allow greater understanding
and explanation of potential clinical outcomes as well as
barriers and enablers that engage with the intervention.
The process evaluation will provide important narratives
on the role of e-health tools in the patient and care pro-
vider experience. These standalone research ﬁndings
will make a novel contribution to translating ﬁndings
into policy and practice.
Economic evaluation
A cost-effectiveness analysis will be undertaken to
compare the e-health strategy with usual care. The eco-
nomic evaluation will entail two components: a trial-
based economic evaluation and a modelled economic
evaluation of long-term costs and outcomes. The trial-
based economic evaluation will estimate the incremental
cost-effectiveness of the e-health strategy in terms of
quality-adjusted life years (QALY) as measured over the
follow-up period. This will enable an incremental cost
per QALY gained to be estimated. The direct costs of
the intervention over and above usual care, including
training support and software maintenance, will be
assessed. Alongside these will be cost offsets, in which
the difference between the costs incurred in the utilisa-
tion of health services, medications and tests between
treatment groups will be assessed. Data for these costs
will be drawn from automated extracts of health service
records (eg, service utilisation) and from self-reported
questionnaires (eg, events, hospitalisations and quality of
life). Details on medications, laboratory tests and service
utilisation will be costed at prevailing rates.
Hospitalisations will be costed using standard Australian
National Diagnosis Related Groups (AN-DRG) cost
weights.
A modelled economic evaluation will be built onto the
trial to enable quality of life and survival to be examined
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over a longer time frame than the trial follow-up period.
Patients in usual care and the e-health strategy would be
tracked over this extended period to capture various
health states (including death and various cardiovascular
events). Transition across these health states will be
based on probabilities in relation to long-term treatment
effects, safety and disease progression derived from the
trial ﬁndings and/or literature review. Data on costs and
quality of life attached to various health states will also
be drawn from literature review and trial data. With
appropriate discounting, estimates of long-term costs
and outcomes will fold out of the model. Sensitivity ana-
lyses will be conducted on variables such as discount
rate, uncertainty in outcome estimates and assumptions
made in costings. Different pricing scenarios will also be
tested to determine threshold values for achieving cost-
effectiveness, including cost-effectiveness of different
components of the strategy.
ETHICS AND DISSEMINATION
The ﬁndings of this study will be disseminated via the
usual scientiﬁc forums including peer-reviewed publica-
tions and presentations at international conferences.
The study will be administered by the George Institute
for Global Health, with the design and conduct overseen
by a Steering Committee. This committee has expertise
in large-scale clinical trials and qualitative research, eco-
nomic analysis, clinical CVD management and healthy
policy implementation. This study will adhere to the
National Health and Medical Research Council ethical
guidelines for human research.
CONCLUSION
Less than half of all people at highest risk of a CVD
event are receiving and adhering to best practice recom-
mendations to lower their risk. In this project, we will
examine the role of e-health-assisted consumer strategies
as a means of overcoming such health system inefﬁcien-
cies. With the availability of the PCEHR for all
Australians in 2012, consumer-focused e-health is set to
become a key component of the health system. Despite
the scale of this initiative, uptake has been slow and
there is little research on the factors that will support its
uptake. Innovative strategies that are practical to imple-
ment and support negotiation of care between consu-
mers and care providers are therefore urgently needed.
The CONNECT study will generate rigorously evalu-
ated ﬁndings on an issue of national and international
importance. The development of a content rich,
consumer-focused e-health intervention that is fully inte-
grated with the primary healthcare system will greatly
inform the e-health agenda. Equitable access to these
emerging technologies is essential, and this study, quan-
titatively and qualitatively, tests the acceptability and
effectiveness of the intervention for Aboriginal and
Torres Strait Islander peoples and other socioeconomic-
ally disadvantaged groups. The intervention will be
compliant with Australian PCEHR speciﬁcations, thus
allowing for seamless interoperability. This maximises its
viability for large-scale implementation across Australia.
If found to be successful, the CONNECT e-health strat-
egy could be upscaled and expanded to increase compli-
ance with international e-health strategies. The
CONNECT strategy may also have applicability as a stan-
dalone strategy where electronic integration with
primary care is unavailable.
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